Point: It takes COURAGE to alter our belief system

Article Type
Article
Changed
Thu, 07/19/2018 - 09:32
Display Headline
Point: It takes COURAGE to alter our belief system
Interpreting the COURAGE trial
Author(s)
William E. Boden, MD
Article PDF
content_74_623.pdf
Author and Disclosure Information

William E. Boden, MD
Professor of Medicine and Preventive Medicine, University at Buffalo Schools of Medicine and Public Health; Medical Director, Cardiovascular Services, Kaleida Health; Chief of Cardiology, Buffalo General and Millard Fillmore Hospitals, Buffalo, NY; Co-principal Investigator, Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial

Address: William E. Boden, MD, Division of Cardiology, Buffalo General Hospital, SUNY at Buffalo School of Medicine, 100 High Street, Buffalo, NY 14203; e-mail: wboden@kaleidahealth.org

Dr. Boden has disclosed that he has received consulting fees or honoraria from Abbott Laboratories, Bristol-Myers Squibb, CV Therapeutics, Merck, PDL BioPharma, and Pfizer.

Issue
Cleveland Clinic Journal of Medicine - 74(9)
Publications
Cleveland Clinic Journal of Medicine
Topics
Cardiology
Page Number
623-625, 629-633
Sections
Editorial
Author(s)
William E. Boden, MD
Author(s)
William E. Boden, MD
Author and Disclosure Information

William E. Boden, MD
Professor of Medicine and Preventive Medicine, University at Buffalo Schools of Medicine and Public Health; Medical Director, Cardiovascular Services, Kaleida Health; Chief of Cardiology, Buffalo General and Millard Fillmore Hospitals, Buffalo, NY; Co-principal Investigator, Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial

Address: William E. Boden, MD, Division of Cardiology, Buffalo General Hospital, SUNY at Buffalo School of Medicine, 100 High Street, Buffalo, NY 14203; e-mail: wboden@kaleidahealth.org

Dr. Boden has disclosed that he has received consulting fees or honoraria from Abbott Laboratories, Bristol-Myers Squibb, CV Therapeutics, Merck, PDL BioPharma, and Pfizer.

Author and Disclosure Information

William E. Boden, MD
Professor of Medicine and Preventive Medicine, University at Buffalo Schools of Medicine and Public Health; Medical Director, Cardiovascular Services, Kaleida Health; Chief of Cardiology, Buffalo General and Millard Fillmore Hospitals, Buffalo, NY; Co-principal Investigator, Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial

Address: William E. Boden, MD, Division of Cardiology, Buffalo General Hospital, SUNY at Buffalo School of Medicine, 100 High Street, Buffalo, NY 14203; e-mail: wboden@kaleidahealth.org

Dr. Boden has disclosed that he has received consulting fees or honoraria from Abbott Laboratories, Bristol-Myers Squibb, CV Therapeutics, Merck, PDL BioPharma, and Pfizer.

Article PDF
content_74_623.pdf
Article PDF
content_74_623.pdf
Related Articles
Point and Counterpoint: Is medical therapy as good as PCI in stable angina? Two views
Counterpoint: PCI is no better than medical therapy for stable angina? Seeing is not believing
Interpreting the COURAGE trial
Interpreting the COURAGE trial
Issue
Cleveland Clinic Journal of Medicine - 74(9)
Issue
Cleveland Clinic Journal of Medicine - 74(9)
Page Number
623-625, 629-633
Page Number
623-625, 629-633
Publications
Cleveland Clinic Journal of Medicine
Publications
Cleveland Clinic Journal of Medicine
Topics
Cardiology
Article Type
Article
Display Headline
Point: It takes COURAGE to alter our belief system
Display Headline
Point: It takes COURAGE to alter our belief system
Sections
Editorial
PURLs Copyright

Disallow All Ads
Alternative CME
Use ProPublica
Article PDF Media
Subscribe to William E. Boden, MD